Tamsulosin

Các tên gọi khác (6 ) :

(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
Tamsulosin
Tamsulosina
Tamsulosine
Tamsulosinum

Thuốc chống ung thư và tác động vào hệ thống miễn dịch

Thuốc Gốc

Small Molecule

CAS: 106133-20-4

ATC: G04CA02

ĐG : Actavis Group , http://www.actavis.com

CTHH: C₂₀H₂₈N₂O₅S

PTK: 408.512

Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.

Nhận Dạng Quốc Tế & Đặc Tính Hóa Học

Công thức hóa học

C₂₀H₂₈N₂O₅S

Phân tử khối

408.512

Monoisotopic mass

408.171892706

InChI

InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1

InChI Key

InChIKey=DRHKJLXJIQTDTD-OAHLLOKOSA-N

IUPAC Name

5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide

Traditional IUPAC Name

tamsulosin

SMILES

CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O

Độ tan chảy

226-228 °C (HCl salt)

Độ hòa tan

Sparingly soluble in water

logP

2.3

logS

-4.8

pKa (strongest acidic)

9.93

pKa (Strongest Basic)

9.28

PSA

99.88 Å²

Refractivity

108.86 m³·mol^-1

Polarizability

43.95 Å³

Rotatable Bond Count

H Bond Acceptor Count

H Bond Donor Count

Physiological Charge

Number of Rings

Bioavailability

Rule of Five

true

Ghose Filter

true

Dược Lực Học : Tamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a racemic mixture of 2 isomers, and is pharmacologically related to doxazocin, prazosin, and terazosin. However, unlike these drugs, tamsulosin has a higher affinity for the alpha-1A- adrenergic receptors, which are located in vascular smooth muscle. Studies show that tamsulosin has about 12 times greater affinity for alpha-1 adrenergic receptors in the prostate than those in the aorta, which may result in a reduced incidence of adverse cardiovascular effects.

Cơ Chế Tác Dụng : Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate. Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate, and thus decreases urinary outflow resistance in men.

Dược Động Học :

▧ Absorption :
Absorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.
▧ Volume of Distribution :
* 16 L [intravenous administration to ten healthy male adults]
▧ Protein binding :
94%-99%
▧ Metabolism :
Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established.
▧ Route of Elimination :
Tamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion. On administration of the radiolabeled dose of tamsulosin hydrochloride to four healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours.
▧ Half Life :
5-7 hours
▧ Clearance :
* 2.88 L/h

Độc Tính : LD₅₀ = 650 mg/kg (in rats)

Chỉ Định : Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)

Tương Tác Thuốc :

Alfuzosin Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
Amiodarone Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed.
Amprenavir Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amprenavir is initiated, discontinued, or dose changed.
Aprepitant Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed.
Atazanavir Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed.
Caffeine Caffeine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Caffeine is initiated, discontinued, or dose changed.
Chloroquine Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed.
Chlorpromazine Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chlorpromazine is initiated, discontinued, or dose changed.
Cimetidine Cimetidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cimetidine is initiated, discontinued, or dose changed.
Cinacalcet Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cinacalcet is initiated, discontinued, or dose changed.
Clarithromycin Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clarithromycin is initiated, discontinued, or dose changed.
Clomipramine Clomipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clomipramine is initiated, discontinued, or dose changed.
Clotrimazole Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed.
Clozapine Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed.
Cocaine Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cocaine is initiated, discontinued, or dose changed.
Conivaptan Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Conivaptan is initiated, discontinued, or dose changed.
Cyclosporine Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed.
Dapiprazole Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Dapiprazole, may result in additive antihypertensive effects. Combination therapy is not recommended.
Darifenacin Darifenacin, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darifenacin is initiated, discontinued, or dose changed.
Darunavir Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darunavir is initiated, discontinued, or dose changed.
Delavirdine Delavirdine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Delavirdine is initiated, discontinued, or dose changed.
Desipramine Desipramine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Desipramine is initiated, discontinued, or dose changed.
Diltiazem Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed.
Diphenhydramine Diphenhydramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diphenhydramine is initiated, discontinued, or dose changed.
Doxazosin Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
Doxycycline Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed.
Duloxetine Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed.
Efavirenz Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed.
Erythromycin Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
Etravirine Etravirine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Etravirine is initiated, discontinued, or dose changed.
Fluconazole Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed.
Fluoxetine Fluoxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluoxetine is initiated, discontinued, or dose changed.
Fosamprenavir Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fosamprenavir is initiated, discontinued, or dose changed.
Haloperidol Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed.
Imatinib Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed.
Imipramine Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed.
Indinavir Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed.
Isoniazid Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed.
Itraconazole Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed.
Ketoconazole Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.
Lapatinib Lapatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lapatinib is initiated, discontinued, or dose changed.
Lidocaine Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed.
Lopinavir Lopinavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lopinavir is initiated, discontinued, or dose changed.
Methadone Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed.
Methimazole Methimazole, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methimazole is initiated, discontinued, or dose changed.
Metronidazole Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed.
Miconazole Miconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Miconazole is initiated, discontinued, or dose changed.
Nefazodone Nefazodone, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nefazodone is initiated, discontinued, or dose changed.
Nelfinavir Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nelfinavir is initiated, discontinued, or dose changed.
Nicardipine Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed.
Nilotinib Nilotinib, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nilotinib is initiated, discontinued, or dose changed.
Norfloxacin Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed.
Paroxetine Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed.
Pergolide Pergolide, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pergolide is initiated, discontinued, or dose changed.
Phenoxybenzamine Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phenoxybenzamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
Phentolamine Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phentolamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
Pioglitazone Pioglitazone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pioglitazone is initiated, discontinued, or dose changed.
Posaconazole Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Posaconazole is initiated, discontinued, or dose changed.
Prazosin Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
Pyrimethamine Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed.
Quinidine Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed.
Quinine Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed.
Ranolazine Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed.
Ritonavir Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed.
Saquinavir Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed.
Sertraline Sertraline, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sertraline is initiated, discontinued, or dose changed.
Silodosin Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended.
Sitaxentan Sitaxsentan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sitaxsentan is initiated, discontinued, or dose changed.
Tadalafil Tadalafil may enhance the hypotensive effect of Tamsulosin. Monitor for hypotension during concomitant therapy.
Telithromycin Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed.
Terazosin Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
Terbinafine Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Terbinafine is initiated, discontinued, or dose changed.
Tetracycline Tetracycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tetracycline is initiated, discontinued, or dose changed.
Thioridazine Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.
Ticlopidine Ticlopidine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ticlopidine is initiated, discontinued, or dose changed.
Tranylcypromine Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tranylcypromine is initiated, discontinued, or dose changed.
Trazodone Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed.
Vardenafil Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Tamsulosin, may occur. Monitor for hypotension during concomitant therapy.
Verapamil Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed.
Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed.

Liều Lượng & Cách Dùng : Capsule, extended release - Oral
Tablet, extended release - Oral

Dữ Kiện Thương Mại

Giá thị trường

Biệt dược thương mại : Tamsulosin hcl 0.4 mg capsule

Giá bán buôn : USD >4.3

Đơn vị tính : capsule
Biệt dược thương mại : Flomax 0.4 mg capsule

Giá bán buôn : USD >4.71

Đơn vị tính : capsule
Biệt dược thương mại : Novo-Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.57

Đơn vị tính : capsule
Biệt dược thương mại : Ran-Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.57

Đơn vị tính : capsule
Biệt dược thương mại : Ratio-Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.57

Đơn vị tính : capsule
Biệt dược thương mại : Sandoz Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.57

Đơn vị tính : capsule
Biệt dược thương mại : Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.57

Đơn vị tính : capsule
Biệt dược thương mại : Flomax Cr 0.4 mg Extended-Release Tablet

Giá bán buôn : USD >0.63

Đơn vị tính : tablet
Biệt dược thương mại : Mylan-Tamsulosin 0.4 mg Sustained-Release Capsule

Giá bán buôn : USD >0.63

Đơn vị tính : capsule

Nhà Sản Xuất

Công ty : Hemofarm

Sản phẩm biệt dược : Betamsal
Công ty : Ranbaxy

Sản phẩm biệt dược : Contiflo XL
Công ty : Boehringer Ingelheim

Sản phẩm biệt dược : Flomax
Công ty : Astellas

Sản phẩm biệt dược : Flomaxtra
Công ty : Astellas

Sản phẩm biệt dược : Harnal D
Công ty : Square

Sản phẩm biệt dược : Maxrin
Công ty : Boehringer Ingelheim

Sản phẩm biệt dược : Mecir
Công ty : Astellas

Sản phẩm biệt dược : Omexel
Công ty : Jelfa

Sản phẩm biệt dược : Omipro
Công ty : Astellas

Sản phẩm biệt dược : Omix
Công ty : Astellas Pharma Europe

Sản phẩm biệt dược : Omnic
Công ty : Boehringer Ingelheim

Sản phẩm biệt dược : Pradif
Công ty : Ranbaxy

Sản phẩm biệt dược : Ranomax
Công ty : Aversi

Sản phẩm biệt dược : Salover
Công ty : Boehringer Ingelheim

Sản phẩm biệt dược : Secotex
Công ty : Actavis

Sản phẩm biệt dược : Stronazon
Công ty : Actavis

Sản phẩm biệt dược : Tamsact
Công ty : Apex

Sản phẩm biệt dược : Tamsol
Công ty : Aspen Pharmacare

Sản phẩm biệt dược : Tamsul
Công ty : Celeris

Sản phẩm biệt dược : Urimax

Đóng gói

Công ty : Actavis Group

Website : http://www.actavis.com
Công ty : AQ Pharmaceuticals Inc.

Website : http://www.aqpharmaceuticals.com
Công ty : A-S Medication Solutions LLC

Website : http://orders.a-smeds.com
Công ty : Astellas Pharma Inc.

Website : http://www.astellas.com
Công ty : Atlantic Biologicals Corporation

Website : http://www.atlanticbiologicals.com
Công ty : Boehringer Ingelheim Ltd.

Website : http://www.boehringer-ingelheim.com
Công ty : Bryant Ranch Prepack

Website : http://bryantranchprepack.com
Công ty : Cadila Healthcare Ltd.
Công ty : Cardinal Health

Website : http://www.cardinal.com
Công ty : Diversified Healthcare Services Inc.

Website : http://www.dhscorp.com
Công ty : GlaxoSmithKline Inc.

Website : http://www.gsk.com
Công ty : Global Pharmaceuticals

Website : http://www.globalphar.com
Công ty : Kaiser Foundation Hospital
Công ty : Major Pharmaceuticals

Website : http://www.majorpharmaceuticals.com
Công ty : Mylan

Website : http://www.mylan.com
Công ty : Pharmacy Service Center
Công ty : Physicians Total Care Inc.

Website : http://www.physicianstotalcare.com
Công ty : Preferred Pharmaceuticals Inc.

Website : http://www.preferredpharmaceuticals.com
Công ty : Prepackage Specialists
Công ty : Prepak Systems Inc.

Website : http://www.prepaksys.com
Công ty : Redpharm Drug
Công ty : Resource Optimization and Innovation LLC
Công ty : Sandoz

Website : http://www.sandoz.ca
Công ty : Stat Rx Usa

Website : http://statrxusa.exporterus.com
Công ty : Synthon Pharmaceuticals Inc.

Website : http://www.synthon.com
Công ty : Teva Pharmaceutical Industries Ltd.

Website : http://www.tevapharm.com
Công ty : UDL Laboratories

Website : http://www.udllabs.com
Công ty : Vangard Labs Inc.
Công ty : Wockhardt Ltd.

Website : http://www.wockhardtin.com
Công ty : Zydus Pharmaceuticals

Website : http://www.zydususa.com

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB00706

PubChem Compound

http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=129211

PubChem Substance

http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507763

KEGG Compound

http://www.genome.jp/dbget-bin/www_bget?cpd:C07124

ChemSpider

http://www.chemspider.com/Chemical-Structure.114457.html

National Drug Code Directory

http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0597-0058-01

PharmGKB

http://www.pharmgkb.org/drug/PA451583

Wikipedia

http://en.wikipedia.org/wiki/Tamsulosin

RxList

http://www.rxlist.com/cgi/generic2/tamsul.htm

Drugs.com

http://www.drugs.com/cdi/tamsulosin.html

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading